Towards Healthcare
Autologous Cell Therapy Market Expand at 18.9% CAGR till 2034

Autologous Cell Therapy Market Growth Outlook with Rapid Expansion and 18.9% CAGR in the Coming Decade

According to forecasts, the global autologous cell therapy market will grow from USD 9.6 billion in 2024 to USD 54.21 billion by 2034, with an expected CAGR of 18.9%. The autologous cell therapy market is growing due to increasing demand for personalized, patient-specific treatments that offer reduced risk of immune rejection and improved clinical outcomes. North America is dominating the market due to the rising demand for personalized products.

  • Insight Code: 6022
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: August 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Deepa Pandey is a focused and detail-oriented market research professional with growing expertise in the healthcare sector, delivering high-quality insights across therapeutic areas, diagnostics, biotechnology, and healthcare services.

She began her research career at Precedence Research, where she contributed to a wide range of healthcare industry studies, helping build a strong foundation in market intelligence and strategic research. Currently, Deepa plays a critical role at Towards Healthcare, while also extending her research capabilities across Statifacts, supporting cross-industry intelligence initiatives with a focus on healthcare.

Her ability to distill complexity into clarity has made her a trusted contributor to both internal teams and external clients across the healthcare value chain. By combining professionalism with an evolving depth in healthcare research, Deepa consistently adds value to projects that demand critical thinking, market precision, and industry-specific knowledge. Her contributions help organizations navigate the complexities of regulated markets and make data-backed growth decisions.

FAQ's

The autologous cell therapy market stands at USD 11.41 billion in 2025 and is expected to reach USD 54.21 billion by 2034, growing at a CAGR of 18.9% from 2024 to 2034.

North America is currently leading the autologous cell therapy market due to strong research funding, advanced healthcare infrastructure, supportive regulatory pathways, and high adoption of innovative cell-based treatments.

The autologous cell therapy market includes segments such as by therapy type, by application, by end user, by technology, and by region.

Some key players include Novartis AG, Gilead Sciences, Bristol Myers Squibb, Vericel Corporation, and Kolon TissueGene Inc.

Ministry of Health and Family Welfare, Government of India National Institutes of Health FDA WHO Press Information Bureau CDC.